Kayfanda is a medicine used for treating cholestatic pruritus (intense itching due to a build-up of bile) caused by Alagille syndrome in patients aged 6 months and older. Alagille syndrome is an inherited disease in which bile (a fluid produced in the liver that helps to break down fats) cannot drain properly from the liver, resulting in a build-up of bile acid in the liver and blood. One of the symptoms of this build-up is cholestatic pruritus. Kayfanda contains the active substance odevixibat.
Therapeutic Indication
### Therapeutic indication Kayfanda is indicated for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older (see sections 4.4 and 5.1).
Therapeutic Area (MeSH)
ATC Code
A05AX05
ATC Item
odevixibat
Pharmacotherapeutic Group
Bile and liver therapy
Active Substance (Summary)
INN / Common Names
EMA Name
Kayfanda
Medicine Name
Kayfanda
Aliases
N/ANo risk management plan link.
